Randomized Clinical Trial
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 28, 2015; 21(16): 5032-5038
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.5032
Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease
Jae Jin Hwang, Dong Ho Lee, Ae-Ra Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim
Jae Jin Hwang, Dong Ho Lee, Ae-Ra Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, Gyeonggi-do, South Korea
Author contributions: Hwang JJ and Lee DH were responsible for the study conception and design, data analysis and interpretation, and manuscript drafting; Lee AR, Yoon H, Shin CM, Park YS and Kim N critically revised the article for important intellectual content; all the authors reviewed and approved the final version to be published.
Ethics approval: The study was reviewed and approved by the Seoul National University Bundang Hospital Institutional Review Board.
Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest: All authors declare no potential conflicting interests related to this paper.
Data sharing: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dong Ho Lee, MD, Department of Internal Medicine, Seoul National University Bundang Hospital, No. 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Gyeonggi-do, South Korea. dhljohn@yahoo.co.kr
Telephone: + 82-31-7877006 Fax: + 82-31-7874051
Received: October 15, 2014
Peer-review started: October 15, 2014
First decision: November 14, 2014
Revised: November 27, 2014
Accepted: January 16, 2015
Article in press: January 16, 2015
Published online: April 28, 2015
Core Tip

Core tip: This is the first study to evaluate the efficacy of 14-d moxifloxacin-based sequential therapy compared to that of 14-d clarithromycin-based sequential therapy as a first-line eradication treatment of Helicobacter pylori infection. Our study showed that the moxifloxacin-based therapy is effective and shows excellent patient compliance and safety compared with the clarithromycin-based sequential therapy. The high eradication rate, excellent compliance, and safety of the moxifloxacin-based sequential therapy suggest its suitability as an alternative to standard triple therapy.